| abstract |
Summary The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compositions, the synthesis, selection and use of such conjugates for use in cancer therapy or other diseases promoted by cell proliferation, cell migration or inflammation, and which pathology involves angiogenesis or neovascularization. In addition, the invention relates to combination therapy of such diseases in which the treatment comprises use of the conjugates in combination with one or more other treatment modalities including, but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compositions linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analogue or a pyrimidine analogue. |